A new study has found that sexual function in prostate cancer patients on external beam radiation therapy (EBRT) decreases within the first two years post treatment but then stabilizes and does not continuously decline as was previously thought.
Changes in sexual function are some of the more common side effects from prostate cancer treatments, but the degree to which EBRT affects function varies widely, depending on the study.
For the study, researchers at the Jefferson Medical College of Thomas Jefferson University in Philadelphia, the Thomas Jefferson University Hospital Department of Radiation Oncology in Philadelphia and the University of California, Davis, School of Medicine Department of Radiation Oncology in Sacramento, Calif., evaluated 143 prostate cancer patients receiving EBRT who completed baseline data on sexual function before treatment and at follow-up visits.
Patients were analyzed on sexual drive, erectile function, ejaculatory function and overall satisfaction for a median time of about four years.
The researchers found that the strongest predictor of sexual function after treatment was sexual function before treatment and the only statistically significant decrease in function occurred in the first two years after treatment and then stabilized with no significant changes thereafter.
"Treatment-related side effects, especially sexual function, have a significant effect on a patient's quality of life and satisfaction with their overall outcome," Richard Valicenti, senior author on the study and professor and chair of radiation oncology at the University of California, Davis, School of Medicine.
"The results of this study allow patients and their partners to have a fuller understanding of the long-term sexual side effects of EBRT and what they can expect after treatment, which should aid in deciding on a treatment course," he added.
The study appears in the January 1 issue of the International Journal of Radiation Oncology, Biology, Physics.
P Study Examines Interval Colorectal Cancer Despite Regular Colonoscopy Immune Responses to Tetanus Vaccine Unchanged for RA Patients on Rituximab M